Facebook Youtube Instagram
Phone Number

770-971-1533

Patient Portal

Sign-in

GET AN APPOINTMENT

Semaglutide & Tirzepatide

ENT Manifestations of Excess Weight

Weiss ENT started offering GLP injections for weight loss in 2021. We realized there was a need to offer additional means to support weight loss in our sleep apnea, snoring, and acid reflux patients, as increased weight is a notorious cause and aggravator of these conditions.

Did You Know?

  • Excess weight is the most common cause for snoring and sleep apnea in adults
  • ~70% of patients with sleep apnea are overweight
  • ~30% of obese patients suffer from reflux
Weekly Subcutaneous Injections for Weight Management

Semaglutide & Tirzepatide

Semaglutide

Starter, then Month-to-Month

$ 500 3 Month Starter
  • Month 1: 0.25 mg/week
  • Month 2: 0.5 mg/week
  • Month 3: 1.0 mg/week
  • After the Starter, semaglutide is available month-to-month
  • Dosing is variable between 0.25 mg to 2.5 mg
  • Pricing is dependent on dosing
Contact Us

Tirzepatide

Month-to-Month

$ 250 Month
  • Dosing is variable between 2.5 mg to 15 mg
  • Pricing is dependent on dosing
Contact Us

We Are With You Every Step of the Way

Weiss ENT started offering GLP injections for weight loss in 2021. We realized there was a need to offer additional means to support weight loss in our sleep apnea, snoring, and acid reflux patients, as increased weight is a notorious cause and aggravator of these conditions.

  • Pre-filled syringes for easier use.
  • Alcohol wipes for safer injection.
  • Instructional office visit to learn how to safely administer injections at home.
  • Progress and weight checks for safety and efficacy monitoring while on medication.

For safety, office visits with a provider will occur while moving up on dosing. Visits are subject to individual insurance co-pay or self-pay rates.

To start, patients will bring in labs done within the prior 6 months, or labs can be drawn in office. (Lab fees are determined and billed by LabCorp.)

Tirzepatide is dual-acting and works on the same receptor as semaglutide (GLP-1) and an additional receptor, glucose-dependent insulinotropic polypeptide (GIP). Because of this, patients may lose more weight and have less side effects on tirzepatide.

Semaglutide and tirzepatide are in a drug class known as incretin mimetics or GLP (glucagon-like-peptide) agonists. They are injectable medications that are FDA- approved for weight loss and diabetic control. They work by:

Delaying gastric emptying

Food is slowly released into the small intestine from the stomach. This means that smaller portions fill you up sooner and keep you full longer.

Stimulating the release of insulin from the pancreas

Insulin tells our cells to uptake glucose from our blood to use it as energy. Over time, this improves insulin sensitivity and regulates blood sugar levels.

Increasing satiety

GLP agonists work on receptors in the brain that are involved in the control of food intake and reward processing. This is immensely helpful in reducing cravings and binge eating.